Initial data from repeat prescription Phase IIIb trial for Zilretta for osteoarthritis of the knee.
Flexion Therapeutics has reported that the Phase III clinical trial for its lead drug candidate Zilretta (also known as FX006,...
Flexion Therapeutics, Inc.announced that the FDA approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection...
Flexion Therapeutics announced results from a sensitivity analysis evaluating the treatment effects of a single administration of Zilretta (triamcinolone acetonide...
Flexion Therapeutics, Inc. announced an independent evaluation of clinical data for Zilretta
Flexion Therapeutics, Inc.announced that the results from a post-hoc analysis of data from the pivotal Phase III trial of Zilretta...
Flexion Therapeutics, Inc. announced that the FDA has approved a supplemental New Drug Application (sNDA) to update the product label...
Flexion Therapeutics, Inc. announced the findings from a new health economics analysis of Zilretta (also known as FX006), the company's...
Flexion Therapeutics announced that the results from an open-label Phase IIIb clinical trial evaluating the safety and exploratory efficacy of...